• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估入院时及症状出现七天后PAINT、ISARIC4C、CHIS和COVID-GRAM预测评分对COVID-19死亡率的预测效用。

Assessing the Utility of Prediction Scores PAINT, ISARIC4C, CHIS, and COVID-GRAM at Admission and Seven Days after Symptom Onset for COVID-19 Mortality.

作者信息

Tanase Alina Doina, Fnu Oktrian, Cristescu Dan-Mihai, Barata Paula Irina, David Dana, Petrescu Emanuela-Lidia, Bojoga Daliana-Emanuela, Hoinoiu Teodora, Blidisel Alexandru

机构信息

Department of Professional Legislation in Dental Medicine, Faculty of Dental Medicine, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania.

Doctoral School, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania.

出版信息

J Pers Med. 2024 Sep 11;14(9):966. doi: 10.3390/jpm14090966.

DOI:10.3390/jpm14090966
PMID:39338220
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11433631/
Abstract

The COVID-19 pandemic underscores the need for accurate prognostic tools to predict patient outcomes. This study evaluates the effectiveness of four prominent COVID-19 prediction scores-PAINT, ISARIC4C, CHIS, and COVID-GRAM-at two critical time points: at admission and seven days post-symptom onset, to assess their utility in predicting mortality among hospitalized patients. Conducted at the Clinical Emergency Hospital Pius Brînzeu in Timișoara, this retrospective analysis included adult patients hospitalized with confirmed SARS-CoV-2 infection. Eligible patients had complete data for the scores at both time points. Statistical analysis involved ROC curves and logistic regression to assess the scores' predictive accuracy for mortality. The study included 215 patients, split into 139 survivors and 76 non-survivors. At admission, the PAINT, ISARIC4C, CHIS, and COVID-GRAM scores significantly differentiated between the survival outcomes ( < 0.0001). The best cutoff values at admission were 6.26 for PAINT, 7.95 for ISARIC4C, 5.58 for CHIS, and 0.63 for COVID-GRAM, corresponding to sensitivities of 85.47%, 80.56%, 88.89%, and 83.33% and specificities of 77.34%, 82.12%, 75.01%, and 78.45%, respectively. By day seven, the cutoff values increased, indicating deteriorating conditions in patients who eventually succumbed to the virus. The hazard ratios at admission for exceeding these cutoffs were significant: PAINT (HR = 3.45), ISARIC4C (HR = 2.89), CHIS (HR = 4.02), and COVID-GRAM (HR = 3.15), highlighting the scores' abilities to predict severe outcomes. One week post symptom onset, these scores' predictive values and corresponding hazard ratios increased, further validating their prognostic significance over time. The evaluated COVID-19 prediction scores robustly predict mortality at admission and become more predictive by the seventh day of symptom onset. These findings support the use of these scores in clinical settings to facilitate early identification and intervention for high-risk patients, potentially improving patient outcomes during the ongoing global health crisis.

摘要

新冠疫情凸显了准确预测患者预后的工具的必要性。本研究评估了四种著名的新冠预测评分——PAINT、ISARIC4C、CHIS和COVID - GRAM——在两个关键时间点(入院时和症状出现后七天)的有效性,以评估它们在预测住院患者死亡率方面的效用。这项回顾性分析在蒂米什瓦拉的皮乌斯·布林泽乌临床急诊医院进行,纳入了确诊感染SARS-CoV-2的成年住院患者。符合条件的患者在两个时间点都有完整的评分数据。统计分析采用ROC曲线和逻辑回归来评估评分对死亡率的预测准确性。该研究包括215名患者,分为139名幸存者和76名非幸存者。入院时,PAINT、ISARIC4C、CHIS和COVID - GRAM评分在生存结果之间有显著差异(<0.0001)。入院时的最佳临界值分别为:PAINT为6.26,ISARIC4C为7.95,CHIS为5.58,COVID - GRAM为0.63,相应的灵敏度分别为85.47%、80.56%、88.89%和83.33%,特异性分别为77.34%、82.12%、75.01%和78.45%。到第七天,临界值升高,表明最终死于病毒的患者病情恶化。入院时超过这些临界值的风险比具有显著性:PAINT(HR = 3.45)、ISARIC4C(HR = 2.89)、CHIS(HR = 4.02)和COVID - GRAM(HR = 3.15),突出了这些评分预测严重结果的能力。症状出现一周后,这些评分的预测价值和相应的风险比增加,进一步证实了它们随时间的预后意义。所评估的新冠预测评分能够有力地预测入院时的死亡率,并且在症状出现后第七天预测性更强。这些发现支持在临床环境中使用这些评分,以便于早期识别和干预高危患者,在当前全球健康危机期间可能改善患者预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d9e/11433631/f9b5c9dced20/jpm-14-00966-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d9e/11433631/b959dc1cd65b/jpm-14-00966-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d9e/11433631/f9b5c9dced20/jpm-14-00966-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d9e/11433631/b959dc1cd65b/jpm-14-00966-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d9e/11433631/f9b5c9dced20/jpm-14-00966-g002.jpg

相似文献

1
Assessing the Utility of Prediction Scores PAINT, ISARIC4C, CHIS, and COVID-GRAM at Admission and Seven Days after Symptom Onset for COVID-19 Mortality.评估入院时及症状出现七天后PAINT、ISARIC4C、CHIS和COVID-GRAM预测评分对COVID-19死亡率的预测效用。
J Pers Med. 2024 Sep 11;14(9):966. doi: 10.3390/jpm14090966.
2
Evaluating the Utility of Clinical Scores APACHE, CURB, SOFA, and NEWS2 at Admission and 5-Days after Symptom Onset in Predicting Severe COVID-19 in Patients with Diabetes.评估临床评分系统APACHE、CURB、SOFA和NEWS2在糖尿病患者入院时及症状出现后5天对预测重症新型冠状病毒肺炎的效用。
J Pers Med. 2024 Aug 16;14(8):868. doi: 10.3390/jpm14080868.
3
4
The informative value of CD3+CD4+ and CD3+CD8+ T-cell count and cHIS scale as predictors of severe COVID-19 when using interleukin-6 receptor blockers in the in-hospital setting.在院内环境中使用白细胞介素 6 受体阻滞剂时,CD3+CD4+和 CD3+CD8+T 细胞计数和 cHIS 评分作为严重 COVID-19 预测因子的信息价值。
Ter Arkh. 2022 Dec 26;94(11):1294-1302. doi: 10.26442/00403660.2022.11.202002.
5
Assessment of Admission COVID-19 Associated Hyperinflammation Syndrome Score in Critically-Ill COVID-19 Patients.评估危重症 COVID-19 患者入院时 COVID-19 相关超高炎症综合征评分。
J Intensive Care Med. 2023 Jan;38(1):70-77. doi: 10.1177/08850666221131265. Epub 2022 Oct 10.
6
Machine learning algorithms for predicting COVID-19 mortality in Ethiopia.用于预测埃塞俄比亚 COVID-19 死亡率的机器学习算法。
BMC Public Health. 2024 Jun 28;24(1):1728. doi: 10.1186/s12889-024-19196-0.
7
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
8
Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.奥密克戎 BA.2 波期间香港住院的 COVID-19 患者无入院时吸氧需求的患者中早期莫努匹韦或奈玛特韦-利托那韦的真实世界疗效:一项回顾性队列研究。
Lancet Infect Dis. 2022 Dec;22(12):1681-1693. doi: 10.1016/S1473-3099(22)00507-2. Epub 2022 Aug 24.
9
Convalescent plasma for people with COVID-19: a living systematic review.COVID-19 患者恢复期血浆治疗:一项实时系统评价。
Cochrane Database Syst Rev. 2023 May 10;5(5):CD013600. doi: 10.1002/14651858.CD013600.pub6.
10
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.用于 SARS-CoV-2 感染诊断的快速、即时抗原检测。
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.

引用本文的文献

1
Comparative Analysis of qSOFA, PRIEST, PAINT, and ISARIC4C Scores in Predicting Severe COVID-19 Outcomes Among Patients Aged over 75 Years.qSOFA、PRIEST、PAINT和ISARIC4C评分在预测75岁以上COVID-19患者严重预后中的比较分析
Diseases. 2024 Nov 28;12(12):304. doi: 10.3390/diseases12120304.

本文引用的文献

1
Predictive value of the neutrophil-to-lymphocyte ratio in the prognosis and risk of death for adult sepsis patients: a meta-analysis.中性粒细胞与淋巴细胞比值对成人脓毒症患者预后和死亡风险的预测价值:一项荟萃分析。
Front Immunol. 2024 Mar 18;15:1336456. doi: 10.3389/fimmu.2024.1336456. eCollection 2024.
2
ISARIC-4C Mortality Score overestimates risk of death due to COVID-19 in Australian ICU patients: a validation cohort study.ISARIC-4C死亡率评分高估了澳大利亚重症监护病房患者因新冠肺炎死亡的风险:一项验证队列研究。
Crit Care Resusc. 2023 Oct 18;23(4):403-413. doi: 10.51893/2021.4.OA5. eCollection 2021 Dec 6.
3
Measuring unequal distribution of pandemic severity across census years, variants of concern and interventions.
衡量大流行严重程度在普查年份、关注变种和干预措施方面的不平等分布。
Popul Health Metr. 2023 Oct 29;21(1):17. doi: 10.1186/s12963-023-00318-6.
4
What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms.有哪些当前的抗 COVID-19 药物?从传统到智能的分子机制。
Virol J. 2023 Oct 24;20(1):241. doi: 10.1186/s12985-023-02210-z.
5
Comparison of COVID-19 vaccine policies and their effectiveness in Korea, Japan, and Singapore.比较韩国、日本和新加坡的 COVID-19 疫苗政策及其效果。
Int J Equity Health. 2023 Oct 20;22(1):224. doi: 10.1186/s12939-023-02034-x.
6
Utility of the 4C ISARIC mortality score in hospitalized COVID-19 patients at a large tertiary Saudi Arabian center.4C ISARIC死亡率评分在沙特阿拉伯一家大型三级中心住院的COVID-19患者中的效用。
Multidiscip Respir Med. 2023 Aug 4;18:917. doi: 10.4081/mrm.2023.917. eCollection 2023 Jan 17.
7
Acute and post-acute sequelae of SARS-CoV-2 infection: a review of risk factors and social determinants.SARS-CoV-2 感染的急性和后期后遗症:风险因素和社会决定因素的综述。
Virol J. 2023 Jun 16;20(1):124. doi: 10.1186/s12985-023-02061-8.
8
External validation of the ISARIC 4C Mortality Score to predict in-hospital mortality among patients with COVID-19 in a Canadian intensive care unit: a single-centre historical cohort study.加拿大重症监护病房 COVID-19 患者院内死亡率预测的 ISARIC 4C 死亡率评分的外部验证:一项单中心历史队列研究。
Can J Anaesth. 2023 Aug;70(8):1362-1370. doi: 10.1007/s12630-023-02512-4. Epub 2023 Jun 8.
9
Is the 4C Score Still a Valid Item to Predict In-Hospital Mortality in People with SARS-CoV-2 Infections in the Omicron Variant Era?在奥密克戎变异株时代,4C评分仍是预测新冠病毒感染患者院内死亡率的有效指标吗?
Life (Basel). 2023 Jan 8;13(1):183. doi: 10.3390/life13010183.
10
COVID-19 economic impacts in perspective: A comparison to recent U.S. disasters.透视新冠疫情对经济的影响:与美国近期灾难的比较
Int J Disaster Risk Reduct. 2021 Jun 15;60:102317. doi: 10.1016/j.ijdrr.2021.102317. Epub 2021 May 8.